In the exploratory analysis, patients with wild-type RAS mCRC who were administered Vectibix in combination with Folfox demonstrated an improvement in median overall survival (OS) of 26 months compared to 20.2 months for patients treated with FOLFOX alone (HR = 0.78, 95 percent CI, 0.62-0.99...Tumor response and superior overall survival were found in the 1x10(13) VPs cohort compared to subtherapeutic doses
Syndax Pharmaceuticals Inc., of Waltham, Mass., said Phase II results published in the Journal of Clinical Oncology showed that HDAC inhibitor entinostat extended both progression-free survival (PFS) and overall survival when added to exemestane in postmenopausal women with estrogen receptor-positive breast cancer whose cancer had progressed after treatment with a nonsteroidal aromatase inhibitor
Amgen Inc., of Thousand Oaks, Calif., said the Phase III head-to-head ASPECCT ('763) trial evaluating its Vectibix (panitumumab) vs. Erbitux (cetuximab, Eli Lilly and Co.) as a single agent for the treatment of chemorefractory metastatic colorectal cancer in patients with wild-type KRAS tumors (n = 1 ,010) met its primary endpoint of noninferiority for overall survival...The estimated overall survival hazard ratio (Vectibix/Erbitux) was 0.966 (95 percent CI: 0.839, 1.113) favoring the Vectibix arm
The immunotherapy drug, called ETBX-011, induced an immune response in advanced colorectal cancer patients and gave encouraging overall survival results
Agenus Inc., of Lexington, Mass., said preliminary data from a Phase II trial showed that newly diagnosed glioblastoma multiforme (GBM) patients treated with Prophage G-100 (heat shock protein-peptide complex-96, HSPPC-96) vaccine plus the standard of care showed a 146 percent increase in progression-free survival (PFS) and a 60 percent increase in overall survival (OS) as compared to the standard of care alone...The study will randomize about 130 patients to receive either OGX-427 or placebo in
Median overall survival to date for all 63 patients treated is about nine months, while median overall survival for each of the three randomization schedules is about 10 months for arm G, 10 months for arm H and eight months for arm I. The 30-day mortality for all patients is 5 percent
Active Biotech, of Lund, Sweden, and Ipsen, of Paris, said they now plan to conduct the primary progression-free survival analysis for the 10TASQ10 global Phase III trial of tasquinimod in 2014, at the same time as the first interim overall survival analysis, when more mature data are available
The open-label, pivotal trial will enroll 400 subjects at about 80 sites in Australia, Canada, China, Europe, Latin America and the U.S. The primary endpoint is progression-free survival, and secondary endpoints include overall survival and safety
Further data presented showed that patients with normal levels of alpha-1-acid glycoprotein (AAG) had a longer median overall survival (20.2 months vs. 4.5 months), improved median event-free survival (5.3 months vs. 2.4 months) and a greater overall response rate (24 percent vs. 0 percent) compared to patients with elevated AAG...The primary endpoint is 90-day overall survival, and the safety and tolerability of the two treatment groups will also be compared
Study endpoints include progression-free survival, objective response rate, median overall survival and evaluation of pharmacodynamics tumor markers, in addition to safety
The study also will assess secondary measures of clinical benefit, including progression-free survival, objective response rate and overall survival at six months and 12 months
Secondary objectives of the trial are tumor response rates, overall survival, safety, tolerability and quality of life